Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 14/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 9/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSH | P09668 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465473 | 0.88 | XDH (0.48) | PI4KAPI4K2BPI4K2API4KBCSNK1D | |
| SCHEMBL4474039 | 0.87 | XDH (0.48) | XDHGRM1 | |
| SCHEMBL4472575 | 0.87 | PDE4A (0.44) | PI4KAPI4K2BPI4K2API4KBXDH | |
| SCHEMBL4465552 | 0.86 | XDH (0.40) | PI4KAPI4K2BPI4K2API4KBXDH | |
| SCHEMBL4466877 | 0.86 | XDH (0.50) | PI4KAPI4K2BPI4K2API4KBKMT2A | |
| SCHEMBL4457782 | 0.85 | PDE4A (0.36) | PI4KAPI4K2BPI4K2API4KBKMT2A | |
| SCHEMBL4474196 | 0.85 | RXRA (0.41) | PI4KAPI4K2BPI4K2API4KBXDH | |
| SCHEMBL4472995 | 0.85 | XDH (0.41) | PI4KAPI4K2BPI4K2API4KBXDH | |
| SCHEMBL4463593 | 0.84 | XDH (0.39) | XDHCTSVCTSLCTSHCTSS | |
| SCHEMBL4463439 | 0.84 | XDH (0.38) | PI4KAPI4K2BPI4K2API4KBCSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2009-12-31 | — | — | US | claimed |
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2008-10-30 | — | — | US | claimed |
| CN-100415747-C | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-09-03 | — | — | CN | claimed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | claimed |
| CN-1688578-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | claimed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | claimed |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2009-12-31 | — | — | US | disclosed |
| WO-2009067607-A2 | COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2008-10-30 | — | — | US | disclosed |
| CN-100415747-C | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-09-03 | — | — | CN | disclosed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| CN-1688578-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | disclosed |
| EP-1551837-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | disclosed |
| WO-2004014911-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | PI4KA 453/4885PI4K2B 674/4885PI4K2A 960/4885 |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | PI4KA 212/4885PI4K2B 350/4885PI4K2A 492/4885 |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | PI4KA 453/4885PI4K2B 674/4885PI4K2A 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.